Plenful, a workflow-automation platform for pharmacy and healthcare operations, has secured $50 million in Series B funding, bringing its total raise to $76 million.
Dahner cofounder Mitchell Rales and Arena Holdings co-led the round, with participation from Bessemer Venture Partners, TQ Ventures, Notable Capital, Susa/Kivu Ventures and other investors.
The company will use the funds for product development and to speed up its go-to-market efforts.
Last year, Plenful scored $17 million in Series A investment and, a year before, raised $35 million in Series B funding.
Blood pressure intelligence platform Aktiia, which trades under Hilo on the London Stock Exchange, announced an oversubscribed $42 million Series B funding round, bringing its total raise to more than $100 million.
Earlybird Health and Wellington Partners co-led the round, with participation from new investors Kfund and naturalX Health Ventures, and existing investors Khosla Ventures, redalpine, Molten Ventures, Verve Ventures and Translink Capital.
Christoph Massner, principal at Earlybird Health, will join Hilo’s board of directors.
“Hilo stands at the intersection of medical-grade precision and consumer-centric accessibility. By building on a validated medical device platform and an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability,” Massner said.
“It’s a rare combination that empowers users to take meaningful control of their health with minimal effort. This is especially critical given the enormous medical need: uncontrolled high blood pressure remains one of the leading risk factors for death worldwide.”
Basil Systems, an AI-enabled intelligence platform for life sciences companies, raised $11.5 million in funding in a round led by Golden Ventures.
Hearst Ventures and Argosy Capital participated in the round.
The funds will be used to expand the company’s AI and machine learning platforms and onboard enterprise clients. Basil Systems will also extend its reach across the pharmaceutical and medical device industries.
“Our AI-powered platform transforms that data into real-time answers for the strategic questions that drive product success. We’re not just accelerating workflows and decision making, but creating a new standard for how life sciences companies make critical decisions across innovation, regulatory, safety and commercialization,” Anthony Cirurgiao, CEO and founder of Basil Systems, said in a statement.
Credit: Source link
